Coherus Oncology, Inc. Common Stock (CHRS)

• Market cap: $171M
• 1 day: 8.89%
• 5 days: 11.36%
• 1 month: 37.38%
• 3 months: 91.51%
• 6 months: 65.63%
• Year to date: 5%
• 1 year: 40%
• 5 years: -92.61%
• 10 years: -94.69%
• Sector: Healthcare
• Industry: Biotechnology

About: Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.

Employees: 177

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

220% more call options, than puts

Call options by funds: $128K | Put options by funds: $40K

3% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 33

5% less funds holding

Funds holding: 116 [Q1] → 110 (-6) [Q2]

5.81% less ownership

Funds ownership: 53.57% [Q1] → 47.75% (-5.81%) [Q2]

19% less capital invested

Capital invested by funds: $50.1M [Q1] → $40.4M (-$9.62M) [Q2]

30% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 20

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $4
• Avg. target: $4
• High target: $4

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

Maxim Group Jason McCarthy

$4

Buy Upgraded

4 Sep 2025